FTY720 Reduces Post-ischemic Brain Lymphocyte Influx but Does Not Improve Outcome in Permanent Murine Cerebral Ischemia

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2011 Jun 25

PMID 21701599

Citations 65

Authors

Arthur Liesz

Li Sun

Wei Zhou

Sonke Schwarting

Eva Mracsko

Markus Zorn

Henrike Bauer

Clemens Sommer

Roland Veltkamp

Affiliations

Soon will be listed here.

Abstract

Background: The contribution of neuroinflammation and specifically brain lymphocyte invasion is increasingly recognised as a substantial pathophysiological mechanism after stroke. FTY720 is a potent treatment for primary neuroinflammatory diseases by inhibiting lymphocyte circulation and brain immigration. Previous studies using transient focal ischemia models showed a protective effect of FTY720 but did only partially characterize the involved pathways. We tested the neuroprotective properties of FTY720 in permanent and transient cortical ischemia and analyzed the underlying neuroimmunological mechanisms.

Methodology/principal Findings: FTY720 treatment resulted in substantial reduction of circulating lymphocytes while blood monocyte counts were significantly increased. The number of histologically and flow cytometrically analyzed brain invading T- and B lymphocytes was significantly reduced in FTY720 treated mice. However, despite testing a variety of treatment protocols, infarct volume and behavioural dysfunction were not reduced 7d after permanent occlusion of the distal middle cerebral artery (MCAO). Additionally, we did not measure a significant reduction in infarct volume at 24 h after 60 min filament-induced MCAO, and did not see differences in brain edema between PBS and FTY720 treatment. Analysis of brain cytokine expression revealed complex effects of FTY720 on postischemic neuroinflammation comprising a substantial reduction of delayed proinflammatory cytokine expression at 3d but an early increase of IL-1β and IFN-γ at 24 h after MCAO. Also, serum cytokine levels of IL-6 and TNF-α were increased in FTY720 treated animals compared to controls.

Conclusions/significance: In the present study we were able to detect a reduction of lymphocyte brain invasion by FTY720 but could not achieve a significant reduction of infarct volumes and behavioural dysfunction. This lack of neuroprotection despite effective lymphopenia might be attributed to a divergent impact of FTY720 on cytokine expression and possible activation of innate immune cells after brain ischemia.

Citing Articles

Spatiotemporal sphingosine-1-phosphate receptor 3 expression within the cerebral vasculature after ischemic stroke.

Matuskova H, Porschen L, Matthes F, Lindgren A, Petzold G, Meissner A iScience. 2024; 27(6):110031.

PMID: 38868192 PMC: 11167442. DOI: 10.1016/j.isci.2024.110031.

Long non-coding RNA HOXA11-AS regulates ischemic neuronal death by targeting miR-337-3p/YBX1 signaling pathway: protective effect of dexmedetomidine.

Yan F, Wang P, Yang X, Wang F Aging (Albany NY). 2023; 15(7):2797-2811.

PMID: 37059588 PMC: 10120896. DOI: 10.18632/aging.204648.

Preclinical Evaluation of Fingolimod in Rodent Models of Stroke With Age or Atherosclerosis as Comorbidities.

Diaz Diaz A, Malone K, Shearer J, Moore A, Waeber C Front Pharmacol. 2022; 13:920449.

PMID: 35910379 PMC: 9326401. DOI: 10.3389/fphar.2022.920449.

The Role of Immunosenescence in Cerebral Small Vessel Disease: A Review.

Del Cuore A, Pacinella G, Riolo R, Tuttolomondo A Int J Mol Sci. 2022; 23(13).

PMID: 35806140 PMC: 9266569. DOI: 10.3390/ijms23137136.

Inflammatory Responses After Ischemic Stroke.

DeLong J, Ohashi S, OConnor K, Sansing L Semin Immunopathol. 2022; 44(5):625-648.

PMID: 35767089 DOI: 10.1007/s00281-022-00943-7.

References

Miron V, Schubart A, Antel J . Central nervous system-directed effects of FTY720 (fingolimod). J Neurol Sci. 2008; 274(1-2):13-7. DOI: 10.1016/j.jns.2008.06.031. View

Davies C, Loddick S, Toulmond S, Stroemer R, Hunt J, Rothwell N . The progression and topographic distribution of interleukin-1beta expression after permanent middle cerebral artery occlusion in the rat. J Cereb Blood Flow Metab. 1999; 19(1):87-98. DOI: 10.1097/00004647-199901000-00010. View

Weigert A, Weis N, Brune B . Regulation of macrophage function by sphingosine-1-phosphate. Immunobiology. 2009; 214(9-10):748-60. DOI: 10.1016/j.imbio.2009.06.003. View

Yilmaz G, Arumugam T, Stokes K, Granger D . Role of T lymphocytes and interferon-gamma in ischemic stroke. Circulation. 2006; 113(17):2105-12. DOI: 10.1161/CIRCULATIONAHA.105.593046. View

Michaud J, Im D, Hla T . Inhibitory role of sphingosine 1-phosphate receptor 2 in macrophage recruitment during inflammation. J Immunol. 2010; 184(3):1475-83. PMC: 3068864. DOI: 10.4049/jimmunol.0901586. View

Ecker R, Rogojanu R, Streit M, Oesterreicher K, Steiner G . An improved method for discrimination of cell populations in tissue sections using microscopy-based multicolor tissue cytometry. Cytometry A. 2006; 69(3):119-23. DOI: 10.1002/cyto.a.20219. View

Czech B, Pfeilschifter W, Mazaheri-Omrani N, Strobel M, Kahles T, Neumann-Haefelin T . The immunomodulatory sphingosine 1-phosphate analog FTY720 reduces lesion size and improves neurological outcome in a mouse model of cerebral ischemia. Biochem Biophys Res Commun. 2009; 389(2):251-6. DOI: 10.1016/j.bbrc.2009.08.142. View

Kawai N, Kawanishi M, Okauchi M, Nagao S . Effects of hypothermia on thrombin-induced brain edema formation. Brain Res. 2001; 895(1-2):50-8. DOI: 10.1016/s0006-8993(01)02026-1. View

Massberg S, von Andrian U . Fingolimod and sphingosine-1-phosphate--modifiers of lymphocyte migration. N Engl J Med. 2006; 355(11):1088-91. DOI: 10.1056/NEJMp068159. View

10.

Dirnagl U, Iadecola C, Moskowitz M . Pathobiology of ischaemic stroke: an integrated view. Trends Neurosci. 1999; 22(9):391-7. DOI: 10.1016/s0166-2236(99)01401-0. View

11.

Webb M, Tham C, Lin F, Lariosa-Willingham K, Yu N, Hale J . Sphingosine 1-phosphate receptor agonists attenuate relapsing-remitting experimental autoimmune encephalitis in SJL mice. J Neuroimmunol. 2004; 153(1-2):108-21. DOI: 10.1016/j.jneuroim.2004.04.015. View

12.

Jin R, Yang G, Li G . Inflammatory mechanisms in ischemic stroke: role of inflammatory cells. J Leukoc Biol. 2010; 87(5):779-89. PMC: 2858674. DOI: 10.1189/jlb.1109766. View

13.

Dirnagl U . Inflammation in stroke: the good, the bad, and the unknown. Ernst Schering Res Found Workshop. 2004; (47):87-99. DOI: 10.1007/978-3-662-05426-0_5. View

14.

Meisel C, Schwab J, Prass K, Meisel A, Dirnagl U . Central nervous system injury-induced immune deficiency syndrome. Nat Rev Neurosci. 2005; 6(10):775-86. DOI: 10.1038/nrn1765. View

15.

Arumugam T, Granger D, Mattson M . Stroke and T-cells. Neuromolecular Med. 2005; 7(3):229-42. DOI: 10.1385/NMM:7:3:229. View

16.

Boutin H, LeFeuvre R, Horai R, Asano M, Iwakura Y, Rothwell N . Role of IL-1alpha and IL-1beta in ischemic brain damage. J Neurosci. 2001; 21(15):5528-34. PMC: 6762680. View

17.

Fujino M, Funeshima N, Kitazawa Y, Kimura H, Amemiya H, Suzuki S . Amelioration of experimental autoimmune encephalomyelitis in Lewis rats by FTY720 treatment. J Pharmacol Exp Ther. 2003; 305(1):70-7. DOI: 10.1124/jpet.102.045658. View

18.

Salomone S, Potts E, Tyndall S, Ip P, Chun J, Brinkmann V . Analysis of sphingosine 1-phosphate receptors involved in constriction of isolated cerebral arteries with receptor null mice and pharmacological tools. Br J Pharmacol. 2007; 153(1):140-7. PMC: 2199385. DOI: 10.1038/sj.bjp.0707581. View

19.

Liesz A, Hagmann S, Zschoche C, Adamek J, Zhou W, Sun L . The spectrum of systemic immune alterations after murine focal ischemia: immunodepression versus immunomodulation. Stroke. 2009; 40(8):2849-58. DOI: 10.1161/STROKEAHA.109.549618. View

20.

Turrin N, Rivest S . Tumor necrosis factor alpha but not interleukin 1 beta mediates neuroprotection in response to acute nitric oxide excitotoxicity. J Neurosci. 2006; 26(1):143-51. PMC: 6674332. DOI: 10.1523/JNEUROSCI.4032-05.2006. View